During human NAFLD/NASH, GSDMD and its N-terminal peptide (GSDMD-N) are upregulated, besides MCD-fed Gsdmd–/– mice showed decreased severity of steatosis and inflammation comparing to WT (52). This evidence concerns the gene GSDMD and metabolic dysfunction-associated steatotic liver disease.